Entrada Therapeutics (TRDA) Resumen de Acciones
Entrada Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica cuyo objetivo es transformar la vida de los pacientes estableciendo una nueva clase de medicamentos que actúen sobre dianas intracelulares que durante mucho tiempo se han considerado inaccesibles. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
TRDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Entrada Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$6.04 |
| Máximo en las últimas 52 semanas | US$16.45 |
| Mínimo de 52 semanas | US$4.93 |
| Beta | -0.085 |
| Cambio en 1 mes | -55.46% |
| Variación en 3 meses | -47.06% |
| Cambio de 1 año | -21.46% |
| Variación en 3 años | -52.63% |
| Variación en 5 años | n/a |
| Variación desde la OPV | -74.78% |
Noticias y actualizaciones recientes
Recent updates
DMD Franchise And Ocular Pipeline Will Create Multiple Long Term Genetic Medicine Opportunities
Catalysts About Entrada Therapeutics Entrada Therapeutics is a clinical stage biopharma company developing proprietary genetic medicines for high unmet need diseases, with a focus on neuromuscular and ocular disorders. What are the underlying business or industry changes driving this perspective?Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have continued their recent momentum with a 26% gain in the last...Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts
Summary Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy pipeline, with multiple early-stage clinical programs converging on key data readouts in 2026. Despite widening losses, TRDA maintains a strong cash position of $326.8 million, sufficient to fund operations through 3Q27 and support ongoing R&D. The stock trades at a deep valuation discount due to its large cash balance, but faces amplified risk from clustered 2026 clinical catalysts. Read the full article on Seeking AlphaEntrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 32% But Its Business Still Trails The Industry
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a really impressive month, gaining 32% after a shaky period...Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just released its latest second-quarter report and things are not looking...Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop
To the annoyance of some shareholders, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares are down a considerable 27% in...Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just kicked off its latest yearly results with some very...Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Summary Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 million in reserves and strategic partnerships extend Entrada's runway into 2027, reducing near-term financing risks. ENTR-601-44, targeting Duchenne muscular dystrophy, is entering critical trials, with potential to validate the platform and drive significant market share. Despite scientific and execution risks, successful trials could elevate Entrada's valuation and establish it as a leader in oligonucleotide-based therapies. Read the full article on Seeking AlphaThe Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a horrible month, losing 26% after a relatively good period...There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Entrada Therapeutics, Inc.'s ( NASDAQ:TRDA ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a strong...Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Celebrations may be in order for Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders, with the analysts delivering...Entrada Therapeutics: A Complicated Tale
Summary Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficiency, potentially revolutionizing treatment across various diseases. Despite ongoing FDA issues, analysts remain optimistic about Entrada's prospects, with a well-padded balance sheet and potential for future collaborations. An analysis around Entrada Therapeutics stock follows in the paragraphs below. Read the full article on Seeking AlphaEntrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
The Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) share price has done very well over the last month, posting an excellent...These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
One thing we could say about the analysts on Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) - they aren't optimistic...This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Shareholders in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) may be thrilled to learn that the analysts have just...Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders will have a reason to smile today, with the analysts making...Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
Investors in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) had a good week, as its shares rose 3.1% to close at US$12.50...Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Entrada Therapeutics press release (NASDAQ:TRDA): Q2 GAAP EPS of -$0.74 misses by $0.02. Cash, cash equivalents and marketable securities were $244.3 million as of June 30, 2022, compared to $291.1 million as of December 31, 2021.We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Rentabilidad de los accionistas
| TRDA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -17.5% | -3.0% | -0.3% |
| 1Y | -21.5% | 32.9% | 26.7% |
Rentabilidad vs. Industria: Los resultados de TRDA fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 32.9% el año pasado.
Rentabilidad vs. Mercado: TRDA obtuvo unos resultados inferiores a los del mercado US, que fueron del 26.7% el año pasado.
Volatilidad de los precios
| TRDA volatility | |
|---|---|
| TRDA Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de TRDA ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TRDA ha aumentado de 12% a 19% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 152 | Dipal Doshi | www.entradatx.com |
Entrada Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que aspira a transformar la vida de los pacientes estableciendo una nueva clase de medicamentos que se dirigen a dianas intracelulares que durante mucho tiempo se han considerado inaccesibles. Los candidatos terapéuticos de la empresa, Endosomal Escape Vehicle, se basan en una novedosa terapéutica; una sólida cartera de desarrollo de medicamentos genéticos para el tratamiento potencial de enfermedades neuromusculares y retinianas hereditarias. Sus productos preclínicos incluyen ENTR-601-44; ENTR-601-45; y VX-670.
Resumen de fundamentos de Entrada Therapeutics, Inc.
| Estadísticas fundamentales de TRDA | |
|---|---|
| Capitalización bursátil | US$203.59m |
| Beneficios(TTM) | -US$166.12m |
| Ingresos (TTM) | US$5.74m |
¿Está TRDA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TRDA | |
|---|---|
| Ingresos | US$5.74m |
| Coste de los ingresos | US$141.55m |
| Beneficio bruto | -US$135.81m |
| Otros gastos | US$30.31m |
| Beneficios | -US$166.12m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.61 |
| Margen bruto | -2,366.87% |
| Margen de beneficio neto | -2,895.05% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado TRDA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 18:16 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Entrada Therapeutics, Inc. está cubierta por 10 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ioannis Souroutzidis | Cantor Fitzgerald & Co. |
| Paul Choi | Goldman Sachs |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |